Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Sunovion widens neurology pipeline through $624mm buy of Cynapsus

Executive Summary

Sunovion Pharmaceuticals Inc. acquired public Canadian spec pharma Cynapsus Therapeutics Inc., paying $40.50 in cash per share (a 117% premium), valuing the transaction at $624mm. The deal has been approved by both company boards and is expected to close in Q4 2016.

Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Specialty Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Payment Includes Cash

Related Companies